Mandatory notification of trades
DiaGenic today announce mandatory notification of trades among primary insiders of DiaGenic ASA which took place as part of the allotment of shares in the “Subsequent repair offering”. Reference is made to the notice to the stock exchange on 17 and 18 November 2010 regarding notification of trades among primary insiders which subscribed in the “Subsequent repair offering”, and the notice to the stock exchange on 23 November 2010 regarding allotment of shares in the “Subsequent repair offering”. The transactions are described in detail below.
Atul Shah, board member in DiaGenic ASA, subscribed for 5,006,377 shares through a related company. Shah’s related company was allotted 3.157.816 shares at NOK 0.50 per share in the “Subsequent repair offering”. Post allotment of the shares Shah’s related company will increase its holding in the Company from 1,877,224 shares to 5,035,040 shares.
Dag Christian Christiansen, Director in DiaGenic ASA, subscribed for 250,000 shares in the “subsequent repair offering”, and was allotted 250,000 shares at NOK 0.50 per share. Post allotment of the shares Christiansen’s holding in the Company will increase from 220,000 shares to 470,000 shares.
Derek Tobin, senior scientist in DiaGenic ASA, subscribed for 10,000 shares in the “subsequent repair offering” and was allotted 10,000 shares at NOK 0.50 per share. Post allotment of the shares Tobin’s holding in the Company will increase from 8,000 shares to 18,000 shares.
Erik Christensen, CEO
Telephone: 47 95939918
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com